{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:32:39Z","timestamp":1787509959622,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The goal of this study was to elucidate the anti-pruritic and anti-inflammatory efficacy of ruxolitinib cream in experimentally-induced dermatitis. Atopic dermatitis (AD), the most common chronic relapsing inflammatory skin disease, significantly impairs patients\u2019 quality of life, with pruritus being a common complaint. The sensation of itch results from the interplay between epidermal barrier dysfunction, upregulated immune signaling and the activation of the central nervous system. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a central role in pro-inflammatory cytokine signaling in AD. Ruxolitinib cream is a potent and selective JAK1\/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651). The efficacy of ruxolitinib cream was tested in murine models of acute and chronic dermatitis and was also characterized in an\n                    <jats:italic>ex vivo<\/jats:italic>\n                    human skin dermatitis model. Ruxolitinib cream was highly effective at ameliorating disease symptoms in multiple murine dermatitis models through downregulation of T helper (Th)2-driven inflammation, resulting in reduced skin thickening and decreased itch. Pathway analysis of mouse ear tissue and human skin explants underscored the role for ruxolitinib in ameliorating inflammation and reducing itch\n                    <jats:italic>via<\/jats:italic>\n                    modulation of the JAK-STAT pathway. Together, the data offer a strong rationale for the use of ruxolitinib cream as a potent therapeutic agent for the clinical management of atopic dermatitis.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2020.620098","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T02:37:26Z","timestamp":1613443046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis"],"prefix":"10.3389","volume":"11","author":[{"given":"Monika D.","family":"Scuron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany L.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16934","article-title":"Atopic dermatitis: the skin barrier and beyond","volume":"180","author":"Tsakok","year":"2019","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.19058","article-title":"Sleep disturbance in atopic dermatitis: a case-control study using actigraphy and smartphone-collected questionnaires","volume":"183","author":"Jachiet","year":"2020","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2019.1655137","article-title":"Atopic dermatitis epidemiology and unmet need in the United Kingdom","volume":"31","author":"Cork","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2011.12.024","article-title":"The many faces of Janus kinase","volume":"83","author":"Seavey","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1600372","article-title":"Evolution of Cytokine Receptor Signaling","volume":"197","author":"Liongue","year":"2016","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase Family in Autoimmune Skin Diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/s12079-018-0464-4","article-title":"A network map of IL-33 signaling pathway","volume":"12","author":"Pinto","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"B13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fimmu.2019.00522","article-title":"Pleiotropic Effects of IL-33 on CD4(+) T Cell Differentiation and Effector Functions","volume":"10","author":"Alvarez","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 Axis in Immune Cells during Inflammatory Diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fimmu.2019.00364","article-title":"IL33: Roles in Allergic Inflammation and Therapeutic Perspectives","volume":"10","author":"Chan","year":"2019","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 Cytokines and Atopic Dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J Clin Cell Immunol"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-017-2963-7","article-title":"Inhibition of JAK\/STAT pathway restrains TSLP-activated dendritic cells mediated inflammatory T helper type 2 cell response in allergic rhinitis","volume":"430","author":"Shi","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.12.019","article-title":"Emerging therapies for atopic dermatitis: JAK inhibitors","volume":"78","author":"Cotter","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: From mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/25785826.2019.1642727","article-title":"Novel topical and systemic therapies in atopic dermatitis","volume":"42","author":"Suga","year":"2019","journal-title":"Immunol Med"},{"key":"B24","first-page":"3S","article-title":"Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis","volume":"23","author":"Lynde","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09546634.2019.1577549","article-title":"JAK\/STAT inhibitors for the treatment of atopic dermatitis","volume":"31","author":"Rodrigues","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"B27","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.jid.2019.04.016","article-title":"IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils","volume":"139","author":"Imai","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"21192","DOI":"10.1038\/s41598-020-78292-4","article-title":"Human skin explant model for the investigation of topical therapeutics","volume":"10","author":"Neil","year":"2020","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","volume":"77","author":"Bryan","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"crossref","first-page":"170ra16","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"crossref","first-page":"bau007","DOI":"10.1093\/database\/bau007","article-title":"TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling","volume":"2014","author":"Zhong","year":"2014","journal-title":"Database (Oxford)"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1038\/jid.2014.198","article-title":"TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6","volume":"134","author":"Han","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2014-05-574327","article-title":"IL-7 and TSLP receptors: twisted sisters","volume":"124","author":"Durum","year":"2014","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1008271107","article-title":"Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling","volume":"107","author":"Rochman","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic Dermatitis: Pathophysiology","volume":"1027","author":"David Boothe","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI5669","article-title":"Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis","volume":"103","author":"Spergel","year":"1999","journal-title":"J Clin Invest"},{"key":"B42","article-title":"Inflammasomes and dermatology","volume":"91","author":"Sa","year":"2016","journal-title":"Bras Dermatol"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1016\/j.det.2013.04.008","article-title":"Role of interleukin 1 in atopic dermatitis","volume":"31","author":"Abramovits","year":"2013","journal-title":"Dermatol Clin"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-0376","article-title":"Atopic dermatitis, melatonin, and sleep disturbance","volume":"134","author":"Chang","year":"2014","journal-title":"Pediatrics"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1016\/j.pedn.2018.07.005","article-title":"To Cope with Everyday Life, I Need to Sleep\u201d - A Phenomenographic Study Exploring Sleep Loss in Parents of Children with Atopic Dermatitis","volume":"43","author":"Angelhoff","year":"2018","journal-title":"J Pediatr Nurs"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1002\/9780470942390.mo140295","article-title":"Voluntary Wheel Running in Mice","volume":"5","author":"Goh","year":"2015","journal-title":"Curr Protoc Mouse Biol"},{"key":"B47","doi-asserted-by":"crossref","first-page":"e7830","DOI":"10.1590\/1414-431x20187830","article-title":"Voluntary wheel running: patterns and physiological effects in mice","volume":"52","author":"Manzanares","year":"2018","journal-title":"Braz J Med Biol Res"},{"key":"B48","doi-asserted-by":"crossref","first-page":"e87887","DOI":"10.1371\/journal.pone.0087887","article-title":"T-helper type-2 contact hypersensitivity of Balb\/c mice aggravated by dibutyl phthalate via long-term dermal exposure","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1038\/jid.2014.401","article-title":"Innate lymphoid cells in the skin","volume":"135","author":"Kim","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103086","article-title":"New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeutic Targets","volume":"19","author":"Klonowska","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2019.08.006","article-title":"Interleukin-33 in atopic dermatitis","volume":"96","author":"Imai","year":"2019","journal-title":"J Dermatol Sci"},{"key":"B53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40360-018-0232-3","article-title":"Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model","volume":"19","author":"Fukuyama","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.01.048","article-title":"IL-33 impacts on the skin barrier by downregulating the expression of filaggrin","volume":"135","author":"Seltmann","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"crossref","first-page":"e2343","DOI":"10.1371\/journal.pone.0002343","article-title":"MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses","volume":"3","author":"Beck","year":"2008","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.620098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T02:37:46Z","timestamp":1613443066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.620098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2020.620098"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.620098","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"article-number":"620098"}}